Clinical utility of plasma percent donor-derived cell-free DNA for lung allograft surveillance: A real-world single-center experience.

ABSTRACT:

Background

Plasma percent donor-derived cell-free DNA (%dd-cfDNA) has been investigated as a biomarker of allograft injury after lung transplantation. We sought to determine the clinical utility of %dd-cfDNA as a screen for acute cellular rejection (ACR) and respiratory infections (RIs) among lung transplant recipients (LTRs).

Methods

We retrospectively analyzed %dd-cfDNA results from 95 plasma samples collected from 81 bilateral LTRs >45 days after transplant with a paired transbronchial biopsy performed within 24 hours after sample collection. We calculated sensitivity, specificity, negative predictive value (NPV), and positive predictive value of %dd-cfDNA to detect ACR and RIs and used a generalized estimating equation model to compare %dd-cfDNA between groups.

Result

SUBMITTER: Sindu D 

PROVIDER: S-EPMC11935403 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature